SavedAdd your journal

Journals / Annals of Medical Research / 2021 / Cilt: 28 - Sayı: 10

α-Galactosidase levels in irritable bowel syndrome subtypes and quality of life of patients

Handan Ankarali
Tuba Soysal
Fatih Ermis
Pages
1881–1886
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The mean AG levels of IBS-C and control group were significantly lower than the other groups (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: There is a requirement for a reliable serologic marker that can be used for the diagnosis of Irritable Bowel Syndrome (IBS).
📊
Key Findings & Data:Materials and Methods: 110 adult patients who were diagnosed with IBS were evaluated. 90 patients and 25 healthy volunteers were included.
💡
Conclusion & Impact:Results: The mean AG levels of IBS-C and control group were significantly lower than the other groups (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: There is a requirement for a reliable serologic marker that can be used for the diagnosis of Irritable Bowel Syndrome (IBS). The aim of our study was to research whether serum levels of Alpha-galactosidase (AG) is associated with IBS and to assess quality of life (QOL) of IBS patients. Materials and Methods: 110 adult patients who were diagnosed with IBS were evaluated. 90 patients and 25 healthy volunteers were included. Patients were classified into subtypes: IBS-Diarrhea (IBS-D), IBS-Constipation (IBS-C), IBS-Mixed (IBS-M), and 30 patients were enrolled for each group. We administered the Short Form 36 (SF-36) to participants to evaluate QOL. Serum AG levels of participants was determined. Results: The mean AG levels of IBS-C and control group were significantly lower than the other groups (p

🔖

Cite This Article

Ankarali, H., Soysal, T., Ermis, F. (2022). α-Galactosidase levels in irritable bowel syndrome subtypes and quality of life of patients. Annals of Medical Research, Cilt: 28 - Sayı: 10, 1881–1886. https://ajindex.com/articles/445836

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Lacy, Brian E. Diagnosis and treatment of diarrheapredominant irritable bowel syndrome. Int J Gen Med 2016;9:7
  2. Basnayake, Chamara. Treatment of irritable bowel syndrome. Aust Prescr 2018;41:145
  3. Halland, Magnus; SAITO, Yuri A. Irritable bowel syndrome: new and emerging treatments. bmj, 2015; 350: h1622
  4. Di Stefano, Michele, et al. The effect of oral α-galactosidase on intestinal gas production and gas-related symptoms. Dig Dis Sci 2007;52:78-83
  5. Hıllılä, Markku, et al. Does oral α-galactosidase relieve irritable bowel symptoms?. Scand J Gastroenterol 2016;51:16-21
  6. Lembo AJ, Neri B, Tolley J, et al. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther 2009;29:834-42
  7. Jennifer YL, Biniam K, Farouq M, Brian MT,et al. Improved health-related quality of life after surgical management of severe refractory constipationdominant irritable bowel syndrome. Int Surg 2015;100:63-9
  8. Spiegel BM, Farid M, Esrailian E, et al. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol 2010;105:848-58
  9. Sood R, Gracie DJ, Law GR, et al. Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Aliment Pharmacol Ther 2015;42:491-503
  10. Ruchit S, Alexander C Ford. Combining biomarkers in irritable bowel syndrome: a forward step toward making a positive diagnosis and directing therapy? Gastroenterology 2015;148:1471-3
  11. Mujagic Z, Tigchelaar EF, Zhernakova A, et al. A novel biomarker panel for irritable bowel syndrome and the application in the general population. Scientific reports 2016;6:26420
  12. Pike BL, Paden KA, Alcala AN, et al. Immunological biomarkers in postinfectious irritable bowel syndrome. J Travel Med 2015;22:242-50
  13. Ringel Y, Williams RE, Kalilani L, et al. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2009;7:68-72
  14. Seo AY, Kim N, Oh DH. Abdominal bloating: Pathophysiology and treatment. J Neurogastroenterol Motil 2013;19:433-53
  15. Ong DK, Mitchell SB, Barrett JS, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010;25: 1366-73
  16. Hoffmann B, Schwarz M, Mehta A, et al. Fabry Outcome Survey Euro